AstraZeneca, Merck Get CHMP Go for Lynparza in Pancreatic Cancer

AstraZeneca PLC and Merck & Co. Monday said the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of the cancer drug Lynparza in a form of pancreatic cancer.
The drugmakers said the recommendation covers Lynparza as monotherapy for the maintenance treatment of adults with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and haven’t progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
The indication now awaits approval from the European Commission, which generally follows the CHMP’s recommendations.
AstraZeneca and Merck in 2017 formed a collaboration to co-develop and co-commercialize Lynparza for multiple cancer types.

https://www.marketscreener.com/ASTRAZENECA-PLC-4000930/news/AstraZeneca-Merck-Get-CHMP-Positive-Opinion-for-Lynparza-in-Pancreatic-Cancer-30705274/